Clinical Trials

6 trials
RecentStart dateEnrollment
NIH × Lymphoma, Large B-Cell, Diffuse × Bortezomib × Clear all
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00096005 2014-02-24

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00994500 2013-07-02

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
CNSLymphoidSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Medulloblastoma, Meningioma, Oligodendroglioma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Optic Nerve Glioma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT00103272 2013-06-04

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
74 enrolled
DermatologicLymphoidOther hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Immunoblastic Lymphadenopathy, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00348985 2013-05-03

PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
55 enrolled
DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma